Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.

PloS one - 1 Jan 2014

Lee Jeeyun, Jain Anjali, Kim Phillip, Lee Tani, Kuller Anne, Princen Fred, In-GuDo, Kim Suk Hyeong, Park Joon Oh, Park Young Suk, Singh Sharat, Kim Hee Cheol

Abstract excerpt

BACKGROUND: Oncogenic mutational analysis provides predictive guidance for therapeutics such as anti-EGFR antibodies, but it is successful only for a subset of colorectal cancer (CRC) patients. METHOD: A comprehensive molecular profiling of 120 CRC patients, including 116 primary, 15 liver metastasis, and 1 peritoneal seeding tissue samples was performed to identify the relationship between v-Ki-ras2 Kirsten rat...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Heterogeneity
Share to Neoplasm Metastasis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Recurrence, Local

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-met

Share to ras Proteins

Share to Receptor, IGF Type 1

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 25090459
DOI: 10.1371/journal.pone.0103551
PMCID: PMC4121133

Genes

KRAS
MET
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.PMID 25090459Read ↗

EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance.Semantic proximity Read ↗

Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics.Semantic proximity Read ↗

Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update.Semantic proximity Read ↗

Integrated multi-omics characterization of KRAS mutant colorectal cancer.Semantic proximity Read ↗

Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer.Semantic proximity Read ↗

Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer.Semantic proximity Read ↗

A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.Semantic proximity Read ↗

Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer.Semantic proximity Read ↗

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan.Semantic proximity Read ↗

Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted TherapiesSemantic proximity Read ↗

Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK.Semantic proximity Read ↗

An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.